I think you have same pipe dream as other small biotech owners who think small biotechs have all the leverage in negotiation of partnership with big pharmas.
Cougar was first in class. They got bought out for $894m, far less than what MDVN is worth today tell you one story, self development route isn't necessarily better. The other story was MDVN partnered with Astellas, one with little past experience in oncology, after the initiation of ph3 trial, rather than some other big pharmas tell you MDV3100 didn't generate as much buzz back then as it is right now.
Plus they had already fleeced Pfizer.
Sure, MDVN are still paying half for the useless trials Dimebon is still running. When all said and done, $225m upfront payment MDVN got from PFE would be spent on their Alzheimer and Huntingon trials they had been running.
Market Data 
Markets 
AI
